PortfoliosLab logoPortfoliosLab logo
PLX vs. ORE.TO
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

PLX vs. ORE.TO - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Protalix BioTherapeutics, Inc. (PLX) and Orezone Gold Corporation (ORE.TO). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Different Trading Currencies

PLX is traded in USD, while ORE.TO is traded in CAD. To make them comparable, the ORE.TO values have been converted to USD using the latest available exchange rates.

Returns By Period

In the year-to-date period, PLX achieves a 8.89% return, which is significantly lower than ORE.TO's 45.64% return. Over the past 10 years, PLX has underperformed ORE.TO with an annualized return of -13.01%, while ORE.TO has yielded a comparatively higher 9.17% annualized return.


PLX

1D
-1.51%
1M
-7.98%
YTD
8.89%
6M
13.95%
1Y
22.50%
3Y*
-3.92%
5Y*
-1.74%
10Y*
-13.01%

ORE.TO

1D
-1.16%
1M
31.18%
YTD
45.64%
6M
57.84%
1Y
78.93%
3Y*
25.37%
5Y*
11.78%
10Y*
9.17%
*Multi-year figures are annualized to reflect compound growth (CAGR)

PLX vs. ORE.TO - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
PLX
Protalix BioTherapeutics, Inc.
8.89%-4.26%5.62%29.93%64.72%-77.09%10.67%5.47%-52.96%48.58%
ORE.TO
Orezone Gold Corporation
45.64%189.82%-30.65%-31.00%-2.03%9.90%70.00%21.57%-25.95%43.21%

Correlation

The correlation between PLX and ORE.TO is 0.15, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.16

Correlation (3Y)
Calculated over the trailing 3-year period

0.09

Correlation (5Y)
Calculated over the trailing 5-year period

0.12

Correlation (10Y)
Calculated over the trailing 10-year period

0.08

Correlation (All Time)
Calculated using the full available price history since May 6, 2009

0.07

Fundamentals

Market Cap

PLX:

$162.78M

ORE.TO:

CA$1.75B

EPS

PLX:

$0.19

ORE.TO:

CA$0.14

PE Ratio

PLX:

10.34

ORE.TO:

18.72

PS Ratio

PLX:

2.08

ORE.TO:

3.45

PB Ratio

PLX:

1.72

ORE.TO:

3.22

Total Revenue (TTM)

PLX:

$76.38M

ORE.TO:

CA$478.80M

Gross Profit (TTM)

PLX:

$53.44M

ORE.TO:

CA$224.13M

EBITDA (TTM)

PLX:

$20.91M

ORE.TO:

CA$235.40M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

PLX vs. ORE.TO — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

PLX
PLX Risk / Return Rank: 5353
Overall Rank
PLX Sharpe Ratio Rank: 5353
Sharpe Ratio Rank
PLX Sortino Ratio Rank: 5252
Sortino Ratio Rank
PLX Omega Ratio Rank: 5252
Omega Ratio Rank
PLX Calmar Ratio Rank: 5454
Calmar Ratio Rank
PLX Martin Ratio Rank: 5252
Martin Ratio Rank

ORE.TO
ORE.TO Risk / Return Rank: 7575
Overall Rank
ORE.TO Sharpe Ratio Rank: 7878
Sharpe Ratio Rank
ORE.TO Sortino Ratio Rank: 7373
Sortino Ratio Rank
ORE.TO Omega Ratio Rank: 7272
Omega Ratio Rank
ORE.TO Calmar Ratio Rank: 7979
Calmar Ratio Rank
ORE.TO Martin Ratio Rank: 7676
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

PLX vs. ORE.TO - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Protalix BioTherapeutics, Inc. (PLX) and Orezone Gold Corporation (ORE.TO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


PLXORE.TODifference

Sharpe ratio

Return per unit of total volatility

0.34

1.25

-0.91

Sortino ratio

Return per unit of downside risk

0.92

1.83

-0.90

Omega ratio

Gain probability vs. loss probability

1.12

1.23

-0.11

Calmar ratio

Return relative to maximum drawdown

0.57

2.37

-1.80

Martin ratio

Return relative to average drawdown

1.07

4.75

-3.68

PLX vs. ORE.TO - Sharpe Ratio Comparison

The current PLX Sharpe Ratio is 0.34, which is lower than the ORE.TO Sharpe Ratio of 1.25. The chart below compares the historical Sharpe Ratios of PLX and ORE.TO, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


PLXORE.TODifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

0.34

1.25

-0.91

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.03

0.20

-0.22

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

-0.16

0.14

-0.31

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.07

0.16

-0.22

Drawdowns

PLX vs. ORE.TO - Drawdown Comparison

The maximum PLX drawdown since its inception was -99.91%, roughly equal to the maximum ORE.TO drawdown of -96.92%. Use the drawdown chart below to compare losses from any high point for PLX and ORE.TO.


Loading charts...

Drawdown Indicators


PLXORE.TODifference

Max Drawdown

Largest peak-to-trough decline

-99.91%

-96.92%

-2.99%

Max Drawdown (1Y)

Largest decline over 1 year

-39.68%

-33.45%

-6.23%

Max Drawdown (3Y)

Largest decline over 3 years

-62.96%

-58.97%

-3.99%

Max Drawdown (5Y)

Largest decline over 5 years

-73.21%

-71.66%

-1.55%

Max Drawdown (10Y)

Largest decline over 10 years

-94.37%

-83.35%

-11.02%

Current Drawdown

Current decline from peak

-99.78%

-64.32%

-35.46%

Average Drawdown

Average peak-to-trough decline

-93.66%

-74.85%

-18.81%

Ulcer Index

Depth and duration of drawdowns from previous peaks

21.01%

16.75%

+4.26%

Volatility

PLX vs. ORE.TO - Volatility Comparison

The current volatility for Protalix BioTherapeutics, Inc. (PLX) is 13.87%, while Orezone Gold Corporation (ORE.TO) has a volatility of 15.20%. This indicates that PLX experiences smaller price fluctuations and is considered to be less risky than ORE.TO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


PLXORE.TODifference

Volatility (1M)

Calculated over the trailing 1-month period

13.87%

15.20%

-1.33%

Volatility (6M)

Calculated over the trailing 6-month period

44.36%

47.72%

-3.36%

Volatility (1Y)

Calculated over the trailing 1-year period

66.69%

63.59%

+3.10%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

67.72%

60.20%

+7.52%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

79.33%

65.57%

+13.76%

Dividends

PLX vs. ORE.TO - Dividend Comparison

Neither PLX nor ORE.TO has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

PLX vs. ORE.TO - Financials Comparison

This section allows you to compare key financial metrics between Protalix BioTherapeutics, Inc. and Orezone Gold Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0050.00M100.00M150.00M200.00M20222023202420252026
33.75M
182.89M
(PLX) Total Revenue
(ORE.TO) Total Revenue
Please note, different currencies. PLX values in USD, ORE.TO values in CAD

PLX vs. ORE.TO - Profitability Comparison

The chart below illustrates the profitability comparison between Protalix BioTherapeutics, Inc. and Orezone Gold Corporation over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

20.0%40.0%60.0%80.0%20222023202420252026
87.8%
51.1%
Portfolio components
PLX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Protalix BioTherapeutics, Inc. reported a gross profit of 29.62M and revenue of 33.75M. Therefore, the gross margin over that period was 87.8%.

ORE.TO - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Orezone Gold Corporation reported a gross profit of 93.46M and revenue of 182.89M. Therefore, the gross margin over that period was 51.1%.

PLX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Protalix BioTherapeutics, Inc. reported an operating income of 21.15M and revenue of 33.75M, resulting in an operating margin of 62.7%.

ORE.TO - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Orezone Gold Corporation reported an operating income of 85.37M and revenue of 182.89M, resulting in an operating margin of 46.7%.

PLX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Protalix BioTherapeutics, Inc. reported a net income of 18.32M and revenue of 33.75M, resulting in a net margin of 54.3%.

ORE.TO - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Orezone Gold Corporation reported a net income of 38.91M and revenue of 182.89M, resulting in a net margin of 21.3%.


Frequently Asked Questions


PLX and ORE.TO have a correlation of 0.15, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Portfolio Optimizer

Find the right allocation for PLX and ORE.TO

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer